ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Nodality Wins Backing From Pfizer Venture

by Lisa M. Jarvis
March 29, 2010 | APPEARED IN VOLUME 88, ISSUE 13

Pfizer Venture Investments led a $15.5 million financing round for Nodality, a South San Francisco-based biotech firm developing personalized tests for cancer and autoimmune diseases. Laboratory Corp. of America, Kleiner Perkins Caufield & Byers, TPG Biotech, and Maverick Capital also participated in the round. Nodality was founded on flow cytometry technology devised by Stanford University professor Garry Nolan. The company is developing tests to help doctors determine which treatment is best suited for a particular patient. Its first product is aimed at people with acute myelogenous leukemia.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment